ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 03 May 2017
Last Updated on 03 May 2017
A- A+
Guidance Recommendations
Following an evaluation of gliclazide for the treatment of type 2 diabetes mellitus, gliclazide 80mg immediate release tablet is recommended for listing on the MOH Standard Drug List 1 (SDL1) by the MOH Drug Advisory Committee in view of its better safety profile compared to other sulfonylureas and low annual cost of subsidy.

This recommendation means that subsidies will apply to gliclazide 80mg immediate release tablet for the indications registered in Singapore:
  • Non-insulin-dependent diabetes, in association with an adapted diet, in cases where dietary measures alone provide inadequate control of blood glucose levels.

Gliclazide 60mg modified release tablet is not recommended for listing on the MOH Standard Drug List in view that there is no difference in clinical outcomes for the modified release tablet compared with the immediate release tablet to justify the significant cost difference between the two preparations.

Gliclazide for T2DM (May 2017)